DocumentsDate added
ORIGINAL ARTICLE
Rajeev Kumar1*,Bandana Sharma2,Swati Trivedi3,Ranbeer Kumar Mehta4
1 Associate Professor, Department of Anaesthesiology, Rama Medical College, Kanpur, Uttar Pradesh, India
2 Department of Obstetrics and Gynecology, G.S.V.M. Medical College, Kanpur,Uttar pradesh, India
3 Assistant Professor, Department of Anaesthesiology, Rama Medical College, Kanpur, Uttar Pradesh, India
4 Professor and HOD, Department of Anaesthesiology, Rama Medical College, Kanpur, Uttar Pradesh, India
Address reprint requests to
*Dr. Rajeev Kumar, Associate Professor, Department of Anaesthesiology, Rama Medical College, Kanpur, Uttar Pradesh, India
Article citation: Kumar R, Sharma B,Trivedi S, Mehta RK. The effect of dexmedetomidine on haemodynamic changes, extubation time and sedation during laparoscopic hysterectomy. J Pharm Biomed Sci 2016;06(03):225–229.Available at www.jpbms.info
ABSTRACT
Background and Aim Suppression of deleterious effect of pneumoperitoneum is a very important goal of laparoscopic surgeries. Dexmedetomidine is a highly selective α2-adrenoreceptor agonist that causes centrally mediated reduction of sympathetic nervous system activity and lead to sedation and analgesia. The aim of our study was to evaluate the effect of dexmedetomidine on haemodynamic response of intraoperative events like laryngoscopy, endotracheal intubation, pneumoperitoneum and extubation time, and sedation during and after laproscopic hysterectomy.
Methods A prospective, randomised and double blind study was done on 50 female patients, undergoing laparoscopic total hysterectomy. All patients were randomly allocated into two groups; group D (dexmedetomidine) and group C (normal saline). Group D
received inj dexmedetomidine 1 μg/kg, diluted in 50 ml of normal saline over 15 min of duration and 0.4 μg/kg/h infusion was started till the pneumoperitoneum continues. Group C patients receive normal saline infusion. Parameter recorded was heart rate (HR), systolic blood pressure (SBP), diastolic blood pressure (DBP), mean blood pressure (MAP), SPO2 and ETCO2. Assessment of sedation was done at extubation than every 15 min for 2 h by Ramsay sedation score (RSS).
Results Among haemodynamic profile, mean arterial pressure and HR after drug administration were significantly lower in perioperative period, particularly at intubation and extubation time in dexmedetomidine (group D) as compared with controls (group C). The extubation time was significantly lower in the dexmedetomidine groups than in the control group. No significant change was seen in the sedation score in both the groups.
Conclusion Dexmedetomidine use during laparoscopic hysterectomy leads to attenuation of hemodynamic response to pneumoperitonium and decrease in extubation time with no change in sedation level of the patients.
KEYWORDS dexmedetomidine, laproscopic hysterectomy, pneumoperitonium
REFERENCES
1.Larsen JF, Svendsen FM, Pedersen V. Randomized clinical trial of the effect of pneumoperitoneum on cardiac function and haemodynamics during laparoscopic cholecystectomy. Br J Surg.2004;91(7):848–854.
2.Myre K, Rostrup M, Buanes T, Stokland O. Plasma catecholamines and haemodynamic changes during pneumoperitoneum.Acta Anaesthesiol Scand. 1998;42(3):343–347.
3.Mann C, Boccara G, Pouzeratte Y, Eliet J, Serradel-Le Gal C,Vergnes C, et al. The relationship among carbon dioxide pneumoperitoneum, vasopressin release, and hemodynamic changes. Anesth Analg. 1999;89(2):278–283.
4.Gutt CN, Oniu T, Mehrabi A, Schemmer P, Kashfi A, Kraus T,et al. Circulatory and respiratory complications of carbon dioxide insufflation. Dig Surg. 2004;21:95–105.
5.Mahdavi A, Peiretti M, Dennis S, Nezhat F. Comparison of laparoscopic hysterectomy morbidity for gynecologic, oncologic, and benign gynecologic conditions. JSLS 2006;10:439–442.
6.Toyoyama H, Kariya N, Hase I, Toyoda Y. The use of intravenous nitroglycerin in a case of spasm of the sphincter of Oddi during laparoscopic cholecystectomy. Anesthesiology.2001;94(4):708–709.
7.Koivusalo AM, Scheinin M, Tikkanen I, Yli-Suomu T, Ristkari S,Laakso J, et al. Effects of esmolol on haemodynamic response to CO2 pneumoperitoneum for laparoscopic surgery. Acta Anaesthesiol Scand. 1998;42(5):510–517.
8.Damen SL, Nieuwenhuijs VB, Joosten W, Houweling PL, Clevers GJ. The effects of remifentanil and sufentanil on the quality of recovery after day case laparoscopic cholecystectomy: a randomized blinded trial. J Laparoendosc Adv Surg Tech A. 2004;14(2):87–92.
9.Pandey CK, Priye S, Ambesh SP, Singh S, Singh U, Singh PK. Prophylactic gabapentin for prevention of postoperative nausea and vomiting in patients undergoing laparoscopic cholecystectomy:a randomized, double-blind, placebo-controlled study.J Postgrad Med. 2006;52(2):97–100.
10.Peng PW, Li C, Farcas E, Haley A, Wong W, Bender J, et al. Use of low-dose pregabalin in patients undergoing laparoscopic cholecystectomy. Br J Anaesth. 2010;105(2):155–161.
11.Jee D, Lee D, Yun S, Lee C. Magnesium sulphate attenuates arterial pressure increase during laparoscopic cholecystectomy. Br J Anaesth. 2009;103(4):484–489.
12.Singh M, Choudhury A, Kaur M, Liddle D, Verghese M,Balakrishnan I. The comparative evaluation of intravenous with intramuscular clonidine for suppression of hemodynamic changes in laparoscopic cholecystectomy. Saudi J Anaesth.2013;7(2):181–186.
13.Khanduja S, Ohri A, Panwar M. Dexmedetomidine decreases requirement of thiopentone sodium and pentazocine followed with improved recovery in patients undergoing laparoscopic cholecystectomy. J Anaesthesiol Clin Pharmacol.2014;30(2):208–212.
14.Hall JE, Uhrich TD, Barney JA, Arain SR, Ebert TJ. Sedative, amnestic and analgesic properties of smalldose Dex infusions. Anesth Analg. 2000;90:699–705.
15.Carollo DS, Nossaman BD, Ramadhyani U. Dexmedetomidine:a review of clinical applications. Curr Opin Anaesthesiol. 2008;21:457–461.
16.Bloor BC, Ward DS, Belleville JP, Maze M. Effects of intravenous dexmedetomidine in humans. II. Hemodynamic changes.Anesthesiology. 1992;77:1134–1142.
17.Isik B, Arslan M, Özsoylar O, Akçabay M. The effects of α2‑adrenergic receptor agonist exmedetomidine on hemodynamic response in direct laryngoscopy. Open Otorhinolaryngol J. 2007;1:5–11.
18.Gurbet A, Basagan‑Mogol E, Turker G, Ugun F, Kaya FN, Ozcan B. Intraoperative infusion of dexmedetomidine reduces perioperative analgesic requirements. Can J Anaesth. 2006;53:646–652.
19.Talke P, Lobo E, Brown R. Systemically administered alpha2-agonist-induced peripheral vasoconstriction in humans. Anesthesiology. 2003;99:65–70.
20.Piascik MT, Soltis EE, Piascik MM, Macmillan LB. Alpha-adrenoceptors and vascular regulation: Molecular, pharmacologic and clinical correlates. Pharmacol Ther. 1996;72:215–241.
21.Grewal A. Dexmedetomidine: New avenues. J Anaesthesiol Clin Pharmacol. 2011;27(3):297–302.
22.Ishii H, Kohno T, Yamakura T, Ikoma M, Baba H. Action of dexmedetomidine on the substantia gelatinosa neurons of the rat spinal cord. Eur J Neurosci. 2008;27(12):3182–3190.
23.Roudet C, Mouchet P, Feuerstein C, Savasta M. Normal distribution of alpha 2-adrenoceptors in the rat spinal cord and its modification after noradrenergic denervation: a quantitative autoradiographic study. J Neurosci Res. 1994;39(3):319–329.
24.Stone LS, Broberger C, Vulchanova L, Wilcox GL, Hökfelt T, Riedl MS, et al. Differential distribution of alpha2A and alpha2C adrenergic receptor immunoreactivity in the rat spinal cord. J Neurosci. 1998;18(15):5928–5937.
25.Arain SR, Ebert TJ. The efficacy, side effects, and recovery characteristics of dexmedetomidine versus propofol when used for intraoperative sedation. Anesth Analg. 2002;95(2):461–466.
26.Candiotti KA, Bergese SD, Bokesch PM, Feldman MA, Wisemandle W, Bekker AY; MAC Study Group. Monitored anesthesia care with dexmedetomidine: a prospective, randomized, double-blind, multicenter trial. Anesth Analg. 2010;110(1):47–56.
27.Alex Bekker, Mary K Sturaitis. Dexmedetomidine for neurological surgery. Neurosurgery. 2005;57(1):1–10.
28.Aho M, Erkola O, Kallio A, Scheinin H, Korttila K. Dexmedetomidine for maintenance of anesthesia in patients undergoing abdominal hysterectomy. Anesth Analg. 1992;75:940–946.
29.Parikh DA, Kolli SN, Karnik HS, Lele SS, Tendolkar BA. A prospective randomized double‑blind study comparing dexmedetomidine vs. combination of midazolam–fentanyl for tympanoplasty surgery under monitored anesthesia care. J Anaesthesiol Clin Pharmacol. 2013;29:173–178.
Statement of originality of work: The manuscript has been read and approved by all the authors, the requirements for authorship have been met, and that each author believes that the manuscript represents honest and original work.
Sources of funding: None.
Competing interest / Conflict of interest: The author(s) have no competing interests for financial support, publication of this research, patents, and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
Disclaimer: Any views expressed in this paper are those of the authors and do not reflect the official policy or position of the Department of Defense.
Research article
Suresh V Dange1, Shrikrishna Subhash Shende2*,Balchandra T Rane3,Abhijeet V Tilak4,Moh anish U Vaidya2,Manasi V Limaye2
1 MBBS, MD Pharmacology, DNB Family Medicine, Department of Pharmacology,Dr. D.Y. Patil Medical College, Pimpri, Pune,411018, India
2 MBBS MD, Junior Resident, Department of Pharmacology, Dr. D.Y. Patil Medical College, Pimpri, Pune, 411018, India
3 MBBS, Department of Pharmacology,Dr. D.Y. Patil Medical College, Pimpri,Pune, 411018, India
4 MBBS, MD Pharmacology, Department of Pharmacology, Dr. D.Y. Patil Medical College, Pimpri, Pune, 411018, India
Address reprint requests to
*Dr. Shrikrishna Subhash Shende,
Department of Pharmacology, Dr. D.Y. Patil Medical College, Pimpri, Pune 411018, India
Article citation: Dange SV, Shende SS,Rane BT, Tilak AV, Vaidya MU, Limaye MV. An observational study of the antidiabetic activity of berberine in newly diagnosed type 2 diabetes mellitus patients. J Pharm Biomed Sci 2016;06(03):230–233. Available at www.jpbms.info
Abstract:
Background Suboptimal glycemic control is a common situation in diabetes, regardless of the wide range of drugs available to achieve glycemic targets. There is in fact a growing body of literature on plants used for the treatment of diabetes. In this respect, in the past few years, attempts were made to use natural plant products for the treatment of patients with diabetes.
Berberine is a commonly available as a nutraceutical and it is a potential candidate for diabetes. Methods and Results A total of 30 newly diagnosed type 2 diabetes mellitus patients
were included in the study after obtaining their informed written consent. They were divided into two groups (n = 15 each), receiving either metformin 500 mg/12 h or berberine 500 mg/12 h p.o. for 12 weeks. No other antidiabetic drugs were given. Therapeutic life style measures were common in both groups. Physical examination and estimation of laboratory parameters were done at baseline and after 12 weeks. Laboratory parameters estimated were fasting blood glucose level (FBG), post prandial blood glucose level (PPBG), glycated hemoglobin (GHb), lipid profile, serum alanine transferase and serum creatinine. Berberine treatment significantly reduced FBG, PPBG, GHb levels and there was significant improvement in lipid profile. The results were comparable to those with metformin.
Conclusion Berberine (500 mg twice daily) may be a useful antidiabetic drug.
KEYWORDS antidiabetic activity, berberine, type 2 diabetes mellitus.
Statement of originality of work: The manuscript has been read and approved by all the authors, the requirements for authorship have been met, and that each author believes that the manuscript represents honest and original work.
Sources of funding: None.
Acknowledgement: The free samples of berberine (Berbeshine hydrochloride 500 mg) were provided by Akumentis Healthcare Ltd, Mumbai.
Competing interest / Conflict of interest: The author(s) have no competing interests for financial support, publication of this research, patents, and royalties through this collaborative research.
All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
Disclaimer: Any views expressed in this paper are those of the authors and do not reflect the
official policy or position of the Department of Defense.
REFERENCES
1.Ni YX. Therapeutic effect of berberine on 60 patients with type II diabetes mellitus and experimental research. Zhong Xi Yi Jie He Za Zhi. 1988;8:711–713.
2.Yin J, Gao Z, Liu D, Liu Z, Ye J. Berberine improves glucose metabolism through induction of glycolysis. Am J Physiol Endocrinol Metab. 2008;294:E148–E156.
3.Xie P, Zhou H, Gao Y. The clinical efficacy of berberine in treatment of type 2 diabetes mellitus [article in Chinese]. Chin J Clin Healthcare. 2005;8:402–403.
4.Wei J, Wu J, Jiang J, Wang S, Wang Z. Clinical study on improvement of type 2 diabetes mellitus complicated with fatty liver treatment by berberine [article in Chinese]. Zhong Xi Yi Jie He Ganbing Za Zhi. 2004;14:334–336.
5.Yin J, Xing H, Ye J. Efficacy of berberine in patients with type 2 diabetes. Metabolism. 2008;57(5):712–717.
6.Lan J, Zhao Y, Dong F, Yan Z, Zheng W, Fan J, et al. Metaanalysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension. J Ethnopharmacol. 2015;161:69–81.
7.Zhang Y, Li Y, Zou D, Liu W, Yang J, Zhu N, et al. Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine. J Clin Endocrinol Metab. 2008;93(7):2559–2565.
8.Lee YS, Kim WS, Kim KH, Yoon MJ, Cho HJ, Shen Y, et al. Berberine,a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states. Diabetes. 2006;55:2256–2264.
9.Zhou L, Yang Y, Wang X, Liu S, Shang W, Yuan G, et al. Berberine stimulates glucose transport through a mechanism distinct from insulin. Metabolism. 2007;56:405–412.
10.Yin J, Hu R, Chen M, Tang J, Li F, Yang Y, et al. Effects of berberine on glucose metabolism in vitro. Metabolism. 2002;51:1439–1443.
11.Yin J, Chen M, Tang J, Li F, Zhou L, Yang Y, et al. Effects of berberine on glucose and lipid metabolism in animal experiment. Chin J Diabetes. 2004;12:215–218.
12.Lee YS, Kim WS, Kim KH, Yoon MJ, Cho HJ, Shen Y, et al. Berberine,a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states. Diabetes.2006;55:2256–2264.